Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

GRIPHON Open-Label Extension

UPTRAVI®—The Only Oral Prostacyclin Pathway Therapy With 7-year Survival Estimates1,2

These data are from long-term follow-up and an open-label extension study. These uncontrolled observations do not allow comparison with a control group not given UPTRAVI® and cannot be used to determine the long-term effect of UPTRAVI® on mortality.

In long-term follow-up of patients who were treated with UPTRAVI® in the pivotal study and the open-label extension (N=574), Kaplan-Meier estimates of survival of these patients across the GRIPHON study and the long-term extension study at 1, 2, 5, and 7 years were 92%, 85%, 71%, and 63%, respectively. The median exposure to UPTRAVI® was 3 years.

Patients taking UPTRAVI® had a 63% estimate of survival at 7 years

Overall survival Kaplan-Meier curve for patients treated with UPTRAVI® in GRIPHON and entered into the open-label extension study1,3*

7-year survival mobile curve

Data presented are Kaplan-Meier survival rate estimates (95% CI).